Cabot Short Interest Hits a Year High Ahead of Earnings

Cabot Corporation enters its fiscal fourth-quarter report with short interest at its highest level in over a year, standing out among its closest specialty chemicals peers as the most actively shorted name in the group.

At 9.4% of the free float, CBT's short position dwarfs the comparable figures for FUL, OEC and MTX, which have attracted far less short conviction heading into the print. That 9.4% reading is the product of a 14.4% jump in shorted shares over the past week alone, adding to a 10.1% rise over the past month. The short score reflects this buildup, moving from around 60.5 in late October to 63.4 by October 30, its highest recent reading.

Despite the crowded short position, the borrow market tells a less pressured story. Availability is running at 575%, meaning roughly five shares remain available to borrow for every one already lent out. That is well above the 52-week floor of 362% and leaves ample room for shorts to add without triggering squeeze dynamics. Cost to borrow has eased to 0.46%, down 14% on the week, reinforcing that demand for borrows is not yet outpacing supply.

Where the picture turns more striking is in options. The put/call ratio jumped to 1.06 on November 2, more than four standard deviations above its 20-day average of 0.17. The 20-day average itself shows how unusual this is: for most of October, CBT's PCR was running below 0.13. The sudden shift to a PCR near the 52-week high of 1.28 points to a sharp increase in demand for downside protection in the session immediately before the report.

The stock has moved against that defensive positioning, gaining 3.9% over the past week against a median of roughly 0.4% for its closest peers. That outperformance comes despite a 1.6% pullback over the past month. On valuation, the trailing P/E is near 10x and EV/EBITDA near 6.2x, levels that most analysts have treated as modest for a business with forward earnings momentum. The analyst consensus remains cautious: the mean price target of $90.33, struck as of early October, sits about 19% above the current $75.72. UBS moved its target down to $86 in early October while keeping a Neutral rating, and JP Morgan maintained an Underweight with a $78 target following the August print. American Century and T. Rowe Price were both notable buyers in the September quarter, adding 530,000 and 767,000 shares respectively, while Wellington trimmed its position from 7.8% to 4.7% of the class over the same period.

Wellington's reduction is the most consequential ownership shift in recent months: a move of that scale from a historically committed holder, combined with the CEO's exercise-and-sale of roughly 230,000 shares across August, leaves net insider activity in the past 90 days at a net disposal of just under $19.7 million. The August trades were coded as open-market sales following option exercises, not pre-arranged 10b5-1 plans, which gives them more signal weight than routine compensation disposals.

The print will test whether Cabot's fiscal fourth-quarter results justify the stock's recent outperformance against peers at a moment when short interest is near a multi-year high and options traders have moved sharply toward protection.